FutureGen Biopharmaceutical
China - BeijingPharmaceutical
Focus: FutureGen Biopharmaceutical is a China-based oncology-focused biotech company specializing in antibody-drug conjugates (ADCs) and monoclonal antibodies. The company is in clinical-stage development with no approved products generating revenue.
Profile data last refreshed 2d ago · AI intelligence enriched 2w ago
Open Jobs
0
About FutureGen Biopharmaceutical
AI assessmentNot HiringNo open roles listed right now. Follow FutureGen Biopharmaceutical to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Mid-stage
2 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Phase 1
Clinical Trials (1)
NCT04894825Safety, Tolerability and Pharmacokinetic Profile of M108 Monoclonal Antibody in Patients With Advanced Unresectable Solid Tumors in China
Phase 1Help build intelligence for FutureGen Biopharmaceutical
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.